Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Wojciech Niedzwiedz (Department of Oncology) who has recently been appointed Associate Professor of Oncology, and Rui Monteiro (MRC Molecular Haematology Unit) who has been appointed University Research Lecturer. The title of University Research Lecturer is given in recognition of substantial independent research achievement, along with contribution to the general academic life of the Medical Sciences Division.

 

wojciech_niedzwiedz
rui_montiero
Wojciech Niedzwiedz Rui Monteiro

 

 
 

Similar stories

Spin-out company Alethiomics launches

The enterprise will focus on developing targeted therapies for a specific family of blood cancers.

Study links the onset of circulation to changes in metabolism affecting blood stem cell development

A new paper published in Cell Reports by the de Bruijn Group indicates that the onset of circulation triggers a metabolic switch associated with the maturation of haematopoietic stem cells.

Interview with Excellence Award winner Dr Susan Shapiro

A member of the Oxford Centre For Haematology, Dr Shapiro, was recently interviewed by the Royal College of Pathologists.

Mohsin Badat receives ASH-BSH Abstract Achievement Award

Dr Mohsin Badat, a Clinical Training Research Fellow from the Higgs and Davies Groups has been awarded the ASH-BSH Abstract Achievement Award by the American Society of Haematology and the British Society of Haematology.

Iron integral to the development of life on Earth – and the possibility of life on other planets

A collaboration between researchers at the MRC WIMM and Department of Earth Sciences uncovers the importance of iron for the development of complex life on Earth.

Strong cytotoxic T cell responses to an internal viral component are associated with mild COVID-19 disease

Study from the Dong Group reveals key differences in the adaptive immune responses of patients with mild vs. severe COVID-19, highlighting a potential new vaccine target.